India, Dec. 1 -- Australia's drug regulator has issued new safety alerts for widely used diabetes and weight-loss drugs, including Ozempic, Wegovy, Saxenda, Trulicity and Mounjaro. The Therapeutic Goods Administration (TGA) announced that all GLP-1 receptor agonists will now carry new warnings about possible mental health risks and, in one case, contraception concerns.

The change comes after reports of suicidal thoughts, depression and unusual mood shifts in some patients using these medications, The Guardian reported. The TGA says there is no proven causal link, but the number of reports is significant enough to require "a precautionary approach."

A recent 2024study using the World Health Organization's global database of drug reaction...